Insight into pimecrolimus experience in seborrheic dermatitis: Close follow-up with exact mean cure and remission times and side-effect profile

Journal of Dermatological Treatment

Volumn 20, Issue 4, 2009, Pages 198-202

  Tatlican, Semih ^a,b   Eren, Cemile ^a   Eskioglu, Fatma ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Adverse effects; Pimecrolimus; Seborrheic dermatitis; Treatment efficacy

Indexed keywords

PIMECROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BURNING SENSATION; CREAM; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG USE; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REMISSION; SEBORRHEIC DERMATITIS; SKIN TINGLING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; PRURITUS; TACROLIMUS;

EID: 69049104694     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802684692     Document Type: Article

References (11)

1. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-26.
2. Veraldi S, Menter A., Innocenti M. Treatment of mild to moderate seborrheic dermatitis with MAS064D (Sebclair), a novel topical medical device: Results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol. 2008;22:290-296 (Pubitemid 351255418)
3. Sugita T, Tajima M, Tsubuku H, Tsuboi R, Nishikawa A. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother. 2006;50:2897-2898 (Pubitemid 44198727)
4. Rigopoulos D, Ionnides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: A randomized open-label clinical trial. Br J Dermatol. 2004;151:1071-1075 (Pubitemid 39573897)
5. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment of seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004;30:191-195 (Pubitemid 40082992)
6. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol. 2006;54:1083-1088
7. Firooz A, Solhpour AM, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: A randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142:1066-1067
8. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57:257-264 (Pubitemid 47048856)
9. De Moraes AP, de Arruda EA, Vitoriano MAV, de Moraes Filho MO, Bezerra FA, de Magalhaes Holanda E, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrheic dermatitis infected with HIV J Eur Acad Dermatol Venereol. 2007;21:596-601.
10. Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients. J Korean Med Sci. 2007;22:868-872
11. Koc E, Area E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2008;1:1-5.